Clinical efficacy of colquhounia root tablets in patients with moderate atopic dermatitis

doi:10.11958/20252619

Abstract

Abstract:

Objective To explore the influence of colquhounia root tablets on the clinical efficacy and inflammatory indicators in patients with moderate atopic dermatitis (AD). Methods A total of 80 patients with moderate AD were prospectively included in this study. Patients were randomly divided into the control group and the test group, with 40 patients in each group. Ultimately, 33 patients in the control group and 32 in the test group were completed the study. The control group received oral hydroxyzine hydrochloride tablets and cetirizine hydrochloride capsules, and externally applied mometasone furoate cream and polymyxin B compound ointment. The test group received the same treatment along with oral Colquhounia root tablets (4 tablets per dose, 3 doses per day). All patients underwent 8 weeks of treatment. Clinical response rates were evaluated in both groups. Before and after treatment, peripheral blood samples were taken to measure and calculate the neutrophil/lymphocyte ratio (NLR), eosinophil/lymphocyte ratio (ELR), monocyte/lymphocyte ratio (MLR), platelet/lymphocyte ratio (PLR) and serum total immunoglobulin E (IgE) levels. Additionally, eczema area and severity index (EASI), pruritus numeric rating scale (PP-NRS), investigator global assessment (IGA) and SCORAD scores were recorded. Results The clinical response rate was significantly higher in the test group than that of the control group (68.8% vs. 39.4%, P = 0.033). After treatment, the NLR and IgE levels were significantly lower in the test group than those of the control group (P < 0.05). Furthermore, the reduction in clinical scores (EASI, IGA, SCORAD) were more significant in the test group compared to those of the control group (P < 0.05). There was no significant difference in the incidence of adverse reaction events between the two groups during the treatment period (6.06% vs. 9.38%, χ2=0.251, P=0.672). Conclusion Colquhounia root tablets show significant efficacy in treating moderate atopic dermatitis by improving clinical symptoms and reducing inflammatory markers, and have a relatively high overall safety.

Key words: dermatitis, atopic, colquhounia root tablets, inflammatory markers, clinical efficacy

CLC Number:

R751.05

Figures/Tables 3

References 23

[1]	中华医学会皮肤性病学分会免疫学组. 特应性皮炎的全程管理共识[J]. 中华皮肤科杂志, 2023, 56(1):5-15.
	Immunology Group of the Dermatology and Venereology Branch of the Chinese Medical Association. Consensus on the whole-process management of atopic dermatitis[J]. Chinese Journal of Dermatology, 2023, 56(1):5-15. doi:10.35541/cjd.20220618.
[2]	YU L, LI L. Potential biomarkers of atopic dermatitis[J]. Front Med (Lausanne), 2022,9:1028694. doi:10.3389/fmed.2022.1028694.
[3]	任赵洋, 张华东, 唐晓颇, 等. 火把花根的研究概况[J]. 中医学, 2023, 12(3):643-651.
	REN Z Y, ZHANG H D, TANG X P, et al. Research overview of colquhounia root[J]. Traditional Chinese Medicine, 2023, 12(3):643-651. doi:10.12677/TCM.2023.123099.
[4]	钟颖, 赵潇, 赵建权, 等. 火把花根片药理作用及临床应用研究进展[J]. 药物评价研究, 2021, 44(9):2020-2027.
	ZHONG Y, ZHAO X, ZHAO J Q, et al. Research progress of pharmacological effects and clinical applications of Huobahuagen Tablets[J]. Drug Evaluation Research, 2021, 44(9):2020-2027. doi:10.7501/j.issn.1674-6376.2021.09.032.
[5]	王亚美, 潘淮. 火把花根片治疗面部激素依赖性皮炎120例临床观察[J]. 中国皮肤性病学杂志, 2002, 16(5):314-315.
	WANG Y M, PAN H. Report of fibraurea stem tablet in the treatment of 120 cases with cortcosteroid dependent dermatitis[J]. The Chinese Journal of Dermatovenereology, 2002, 16(5):314-315. doi:10.3969/j.issn.1001-7089.2002.05.013.
[6]	邢飞, 姜波. 盐酸左西替利嗪联合火把花根治疗慢性荨麻疹40例疗效观察[J]. 咸宁学院学报(医学版), 2010, 24(6):510.
	XING F, JIANG B. Clinical observation of 40 cases of chronic urticaria treated with levcetilizine hydrochloride combined with Huobahuagen[J]. Journal of Xianning University(Medical Sciences), 2010, 24(6):510. doi:10.3969/j.issn.1008-0635.2010.06.033.
[7]	韩宪伟, 李铁男, 王强. 火把花根片在皮肤科的临床应用[J]. 中国中西医结合皮肤性病学杂志, 2022, 21(4):357-360.
	HAN XW, LI T N, WANG Q. Clinical application of kniphofia root tablets in dermatology[J]. Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine, 2022, 21(4):357-360. doi:10.3969/j.issn.1672-0709.2022.04.022
[8]	INOKUCHI-SAKATA S, ISHIUJI Y, KATSUTA M, et al. Role of eosinophil relative count and neutrophil-to-lymphocyte ratio in the assessment of severity of atopic dermatitis[J]. Acta Derm Venereol, 2021, 101(7):adv00491. doi:10.2340/00015555-3838.
[9]	LIU P, ZHAO Y, MU Z L, et al. Clinical features of adult/adolescent atopic dermatitis and Chinese criteria for atopic dermatitis[J]. Chin Med J(Engl), 2016, 129(7):757-762. doi:10.4103/0366-6999.178960.
[10]	中华医学会皮肤性病学分会免疫学组,特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020, 53(2):81-88.
	Atopic Dermatitis Working Group, Immunology Group, Chinese Society of Dermatology. Chinese guideline for diagnosis and treatment of atopic dermatitis(2020).[J]. Chinese Journal of Dermatology, 2020, 53(2):81-88. doi:10.35541/cjd.20191000.
[11]	HANIFIN J M, BAGHOOMIAN W, GRINICH E, et al. The eczema area and severity index-a practical guide[J]. Dermatitis, 2022, 33(3):187-192. doi:10.1097/DER.0000000000000895.
[12]	WIKSTRöM L, NILSSON M, BROSTRöM A, et al. Patients' self-reported nausea:validation of the Numerical Rating Scale and of a daily summary of repeated Numerical Rating Scale scores[J]. J Clin Nurs, 2019, 28(5-6):959-968. doi:10.1111/jocn.14705.
[13]	吴波, 朱卓农, 郑丽娟, 等. 苦参碱对特应性皮炎炎症、氧化应激和伤口愈合的影响[J]. 天津医药, 2024, 52(6):566-571.
	WU B, ZHU Z N, ZHENG L J, et al. Effects of matrine on inflammation, oxidative stress and wound healing in atopic dermatitis[J]. Tianjin Med J, 2024, 52(6):566-571. doi:10.11958/20231689.
[14]	中国医师协会皮肤科医师分会, 中华医学会皮肤性病学分会, 中国医疗保健国际交流促进会皮肤医学分会, 等. 特应性皮炎治疗药物应用管理专家共识(2024版)[J]. 中华皮肤科杂志, 2024, 57(2):97-108.
	China Dermatologist Association,Chinese Society of Dermatology,Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care,et al. Expert consensus on the application and management of therapeutic drugs for atopic dermatitis(2024)[J]. Chinese Journal of Dermatology, 2024, 57(2):97-108. doi:10.35541/cjd.20230358.
[15]	THYSSEN J P, CORN G, WOHLFAHRT J, et al. Retrospective markers of paediatric atopic dermatitis persistence after hospital diagnosis:a nationwide cohort study[J]. Clin Exp Allergy, 2019, 49(11):1455-1463. doi:10.1111/cea.13487.
[16]	HAGINO T, SAEKI H, FUJIMOTO E, et al. The eosinophil-to-lymphocyte ratio acts as an indicator for improvement of clinical signs and itch by upadacitinib treatment in atopic dermatitis[J]. J Clin Med, 2023, 12(6):2201. doi:10.3390/jcm12062201.
[17]	JIANG Y, MA W. Assessment of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in atopic dermatitis patients[J]. Med Sci Monit, 2017, 23:1340-1346. doi:10.12659/msm.900212.
[18]	DOGRU M, CITLI R. The neutrophil-lymphocyte ratio in children with atopic dermatitis:a case-control study[J]. Clin Ter, 2017, 168(4):e262-e265. doi:10.7417/T.2017.2017.
[19]	AFSHARI M, KOLACKOVA M, ROSECKA M, et al. Unraveling the skin,a comprehensive review of atopic dermatitis,current understanding,and approaches[J]. Front Immunol, 2024,15:1361005. doi:10.3389/fimmu.2024.1361005.
[20]	宋东红, 马利方, 于洋. 雷公藤红素通过抑制颗粒细胞炎症因子基因表达改善肥胖小鼠生育能力的研究[J]. 天津医药, 2021, 49(2):141-146.
	SONG D H, MA L F, YU Y. Study on the fertility improvement of obese mice by inhibiting granulosa cell inflammation using celastrol[J]. Tianjin Med J, 2021, 49(2):141-146. doi:10.11958/20202104.
[21]	CAO J, LIU H, DING X. Association of Inflammatory indicators and clinical signs and itch in atopic dermatitis patients treated with simiao pill combined with halomethasone cream[J]. J Inflamm Res, 2023, 16:3643-3653. doi:10.2147/JIR.S423131.
[22]	孙坤坤, 韩学超, 孙孝凤, 等. 中医药防治特应性皮炎研究进展[J]. 中国实验方剂学杂志, 2022, 28(5):266-273.
	SUN K K, HAN X C, SUN X F, et al. Prevention and treatment of atopic dermatitis with traditional Chinese medicine:a review[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2022, 28(5):266-273. doi:10.13422/j.cnki.syfjx.20220495.
[23]	刘俊峰, 莫秀梅, 莫美, 等. 中医药临床优势病种探讨——特应性皮炎[J]. 中国实验方剂学杂志, 2025, 31(1):244-252.
	LIU J F, MO X M, MO M, et al. Expert consensus on clinical diseases responding specifically to traditional chinese medicine:atopic dermatitis[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2025, 31(1):244-252. doi:10.13422/j.cnki.syfjx.20242493.

组别	n	NLR			ELR				MLR
组别	n	治疗前	治疗后	Z	治疗前	治疗后		Z	治疗前	治疗后	Z
对照组	33	2.59（1.64，3.37）	2.39（1.40，3.37）	0.509	0.19（0.11，0.32）	0.11（0.06，0.24）		2.689^＊＊	0.23（0.20，0.33）	0.23（0.16，0.30）	1.053
试验组	32	2.15（1.56，2.92）	1.91（1.46，2.23）	2.824^＊＊	0.21（0.13，0.35）	0.12（0.09，0.16）		4.409^＊＊	0.20（0.13，0.32）	0.19（0.14，0.28）	0.490
Z		0.577	1.981^＊		0.577	0.098			1.411	1.050
组别			PLR					IgE（IU/mL）
组别			治疗前	治疗后			Z	治疗前		治疗后	Z
对照组			158.87（125.13，204.39）	143.06（119.30，173.36）			1.402	308（97，410）		273（165，347）	0.670
试验组			140.29（101.93，185.37）	132.67（107.25，161.20）			1.085	332（109，413）		213（65，255）	4.448^＊＊
Z			1.502	1.371				0.361		2.718^＊

组别	n	NLR			ELR				MLR
组别	n	治疗前	治疗后	Z	治疗前	治疗后		Z	治疗前	治疗后	Z
对照组	33	2.59（1.64，3.37）	2.39（1.40，3.37）	0.509	0.19（0.11，0.32）	0.11（0.06，0.24）		2.689^＊＊	0.23（0.20，0.33）	0.23（0.16，0.30）	1.053
试验组	32	2.15（1.56，2.92）	1.91（1.46，2.23）	2.824^＊＊	0.21（0.13，0.35）	0.12（0.09，0.16）		4.409^＊＊	0.20（0.13，0.32）	0.19（0.14，0.28）	0.490
Z		0.577	1.981^＊		0.577	0.098			1.411	1.050
组别			PLR					IgE（IU/mL）
组别			治疗前	治疗后			Z	治疗前		治疗后	Z
对照组			158.87（125.13，204.39）	143.06（119.30，173.36）			1.402	308（97，410）		273（165，347）	0.670
试验组			140.29（101.93，185.37）	132.67（107.25，161.20）			1.085	332（109，413）		213（65，255）	4.448^＊＊
Z			1.502	1.371				0.361		2.718^＊

组别	n		EASI						PP-NRS
组别	n		治疗前		治疗后		Z		治疗前		治疗后		Z
对照组	33		17.0（16.0，18.0）		5.0（3.0，10.0）		4.910^＊＊		6.0（5.0，7.0）		2.0（1.0，4.5）		4.811^＊＊
试验组	32		17.0（16.0，18.8）		3.0（3.0，4.0）		4.853^＊＊		6.0（5.0，7.0）		2.0（1.0，3.0）		4.763^＊＊
Z			0.054		2.431^＊				0.434		0.531
组别		IGA						SCORAD
组别		治疗前		治疗后		Z		治疗前		治疗后		Z
对照组		3（3.0，3.0）		2.0（1.0，2.0）		5.080^＊＊		34.0（30.0，36.0）		6.0（6.0，8.0）		5.025^＊＊
试验组		3（3.0，3.0）		1.0（0.3，2.0）		5.065^＊＊		33.0（30.0，36.0）		6.0（4.0，7.5）		4.944^＊＊
Z		0.714		2.107^＊				0.324		2.098^＊

组别	n		EASI						PP-NRS
组别	n		治疗前		治疗后		Z		治疗前		治疗后		Z
对照组	33		17.0（16.0，18.0）		5.0（3.0，10.0）		4.910^＊＊		6.0（5.0，7.0）		2.0（1.0，4.5）		4.811^＊＊
试验组	32		17.0（16.0，18.8）		3.0（3.0，4.0）		4.853^＊＊		6.0（5.0，7.0）		2.0（1.0，3.0）		4.763^＊＊
Z			0.054		2.431^＊				0.434		0.531
组别		IGA						SCORAD
组别		治疗前		治疗后		Z		治疗前		治疗后		Z
对照组		3（3.0，3.0）		2.0（1.0，2.0）		5.080^＊＊		34.0（30.0，36.0）		6.0（6.0，8.0）		5.025^＊＊
试验组		3（3.0，3.0）		1.0（0.3，2.0）		5.065^＊＊		33.0（30.0，36.0）		6.0（4.0，7.5）		4.944^＊＊
Z		0.714		2.107^＊				0.324		2.098^＊

炎症指标	EASI		PP-NRS评分
炎症指标	治疗前	治疗后	治疗前	治疗后
ELR	0.397^＊＊	0.350^＊＊	0.289^＊	0.436^＊＊
NLR	0.411^＊＊	0.465^＊＊	0.229	0.490^＊＊
MLR	0.346^＊＊	0.115	0.170	-0.008
PLR	0.385^＊＊	0.234	0.266^＊	0.197